Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Our Brands
    • Affimer®
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Research
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Our Brands
    • Affimer®
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Research
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News Investors
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

Investors

20 Sep 2023

Issue of Equity and Total Voting Rights

Investors
20 Sep 2023

Peel Hunt Appointed as Joint Broker

Investors
20 Sep 2023

Appointment of Dr. Christina Coughlin as a consultant

Investors | Therapeutics
19 Sep 2023

Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update

Investors | Therapeutics
06 Sep 2023

Notice of Results

Investors
21 Jul 2023

Issue of Equity and Total Voting Rights

Investors
28 Jun 2023

Result of Annual General Meeting

Investors
28 Jun 2023

Annual General Meeting and Shareholder Event

Investors
21 Jun 2023

Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study

Investors | Therapeutics
19 Jun 2023

Director Appointment

Investors

Posts navigation

Older posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

Consilium
Strategic Communications
85 Gresham Street
London
EC2V 7NQ

Email

Twitter | Linkedin

©2023 Avacta Life Sciences Limited. Registered company no. 06605196.